Business Segments · Research and development - internal
Business Segments — Research and development - internal
Incyte Business Segments — Research and development - internal decreased by 3.5% to $260.18M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.9%, from $228.35M to $260.18M. Over 3 years (FY 2022 to FY 2025), Business Segments — Research and development - internal shows an upward trend with a 10.0% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026Apr 28, 2026
How to read this metric
Higher spending indicates a robust pipeline investment, though it must be balanced against the probability of clinical success.
Detailed definition
This captures the costs incurred for in-house scientific research, clinical trial management, and laboratory operations....
Peer comparison
Standard R&D expense line item for all biotech and pharmaceutical firms.
Metric ID:
incy_segment_reportable_segment_research_and_development_internalHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $184.95M | $184.95M | $184.95M | $184.95M | $203.76M | $203.76M | $203.76M | $203.76M | $223.10M | $234.64M | $250.48M | $249.84M | $228.35M | $236.69M | $250.14M | $269.56M | $260.18M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +10.2% | +0.0% | +0.0% | +0.0% | +9.5% | +5.2% | +6.8% | -0.3% | -8.6% | +3.7% | +5.7% | +7.8% | -3.5% |
| YoY Change | — | — | — | — | +10.2% | +10.2% | +10.2% | +10.2% | +9.5% | +15.2% | +22.9% | +22.6% | +2.4% | +0.9% | -0.1% | +7.9% | +13.9% |
Range$184.95M – $269.56M
CAGR+8.9%
Avg YoY Growth+10.4%
Median YoY Growth+10.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's business segments — research and development - internal?
- Incyte (INCY) reported business segments — research and development - internal of $260.18M in Q1 2026.
- How has Incyte's business segments — research and development - internal changed year-over-year?
- Incyte's business segments — research and development - internal increased by 13.9% year-over-year, from $228.35M to $260.18M.
- What is the long-term trend for Incyte's business segments — research and development - internal?
- Over 3 years (2022 to 2025), Incyte's business segments — research and development - internal has grown at a 10.0% compound annual growth rate (CAGR), from $739.79M to $984.73M.
- What does business segments — research and development - internal mean?
- The cost of conducting research and clinical trials within the company's own facilities.